

Reinventing the Human Body: Biomedical Innovations in Artificial Organ Development

Raagathoorigai S

Sri Chaitanya Techno School, Bengaluru, India

Email: raagathoorigai[at]gmail.com

Abstract: *This review examines major innovations in artificial organ development within biomedical engineering, with emphasis on biomaterials, tissue engineering, 3D bioprinting, and artificial intelligence-assisted technologies. Historical advances and modern systems, including artificial heart and bioartificial liver platforms, are critically discussed. Current progress in manufacturing techniques, device biocompatibility, and clinical translation is evaluated alongside limitations related to donor shortages, immune compatibility, and ethical concerns. The review highlights how emerging interdisciplinary technologies are improving organ functionality and expanding treatment possibilities. Future progress depends on scalable fabrication, intelligent monitoring systems, and translational integration to support accessible and sustainable healthcare solutions.*

Keywords: Biomedical engineering; Artificial organs; 3D bioprinting; Biomaterials; Tissue engineering; Bioartificial liver; Artificial heart; Artificial intelligence in healthcare.

1. Introduction

Biomedical engineering has emerged as an interdisciplinary field that integrates principles of engineering, biology, and medicine to address complex challenges in healthcare. One of its most significant contributions is the development of artificial organs. These organs provide life-saving solutions for patients with organ failure resulting from disease, injury, or congenital conditions. By applying advanced technologies, including biomaterials, biomechanics, tissue engineering, and medical device design, biomedical engineers have enabled the development of artificial organ systems. These systems replicate or support the functions of natural organs. Doctors, scientists, and engineers have come a long way through numerous trials and experiments in restoring defective organs. Over time, artificial organs have shown promising results due to their emerging features. They help address serious issues such as donor shortages, high costs, immune rejection, and ethical conflicts, and improve patient survival rates and quality of life. Despite the advantages, artificial organs have numerous limitations and challenges to overcome. Artificial organs can replace failing organs temporarily or permanently. On a broad basis, artificial organs can be classified into three types with respect to material consumption:

- 1) Mechanical – made of tools and machines
- 2) Biomechanical – partially made of living tissues/cells and machines
- 3) Biological – made of living cells and biodegradable polymers. [1]

This paper aims to examine a comprehensive analysis of recent innovations in artificial organ development, highlighting the pivotal roles of biomaterials, 3D bioprinting, and AI-enabled biomedical technologies. Specifically, how can emerging technologies improve the functionality, accessibility, and long-term viability of artificial organs in modern healthcare?

2. Methodology

2.1. Keywords Used

A structured literature search was conducted to identify relevant studies on artificial organ development. Keywords such as 'artificial organs', '3D bioprinting', 'biomaterials', 'tissue engineering' and 'AI in healthcare' were used. These terms were combined using Boolean operators (AND, OR) to refine the search. The search focused on studies published between 2018 and 2025 to capture recent advancements in the field.

2.2 Databases Used

Relevant articles were retrieved from major academic databases, including PubMed, ScienceDirect, Google Scholar, and IEEE Xplore. These databases were selected due to their strong coverage of biomedical engineering and healthcare research.

2.3 Inclusion Criteria

Studies were included if they were published in English, focused on artificial organ development or related technologies, and provided relevant insights into biomaterials, 3D bioprinting, or AI applications. Both review articles and original research studies were considered.

2.4 Exclusion Criteria

Studies were excluded if they were outdated, not directly related to artificial organ development, or lacked scientific credibility. (e.g., non-peer-reviewed sources).

2.5 Review Approach

A narrative review approach was adopted to synthesize the findings. The selected studies were grouped into key themes, including biomaterials, 3D bioprinting technologies, artificial organ systems, and AI applications in healthcare. This thematic organisation allowed for current advancements and challenges.

Volume 15 Issue 4, April 2026

Fully Refereed | Open Access | Double Blind Peer Reviewed Journal

www.ijsr.net

3. Evolution of Organ Transplantation

Though there were minor transplants like that of the skin, the first ever organ transplant was done on December 23, 1954, in Boston, Massachusetts. The procedure involved a kidney transplant between identical twins, Richard and Ronald Herrick. It was to treat Richard's end-stage renal failure. Despite the initial medical uncertainty of living with a single kidney, the genetic compatibility between the twins increased the likelihood of success. Regardless of widespread disagreement, the surgery performed by Dr Joseph Murray was successful. It marked a significant milestone in medical history. This achievement later contributed to Murray being awarded the Nobel Prize in Physiology or Medicine in 1990.




Figure 1: A picture of Ronald Herrick and Richard Herrick after the successful transplantation

Source: RTE



Figure 2: A picture of Dr Joseph Murray, with his Nobel Prize in Physiology or Medicine in 1990

Source: HarvardMedicine

Ronald and Richard initially recovered well; however, Richard died eight years later due to a heart attack. Despite this outcome, the procedure had a significant impact, increasing awareness and facilitating subsequent transplantations between identical twins. [9] In the following years, many organ transplantations were successfully performed, enhancing human life. The surgery demonstrated that transplanting a major organ was surgically possible and could lead to a prolonged and improved quality of life. This success transformed organ transplantation from an experimental concept into a life-saving treatment option. Additionally, the development of transplanting other organs, including the heart, liver, and lungs, saw successful procedures in the following decades. However, shortly after the wide use of this method, several limitations emerged that significantly constrained transplantation. Nevertheless, researchers' efforts continued, with a sustained focus on improving patient outcomes.

4. Tissue and Biomedical Engineering

Tissue Engineering is a specialised subfield within biomedical engineering. All tissue engineering research falls under biomedical engineering, but not all biomedical engineering involves tissue engineering. In short, biomedical engineering provides the mechanical and electronic framework, while tissue engineering contributes biological components for regenerative functionality.

Tissue Engineering	Biomedical Engineering
It is Cell- and tissue-based.	It is device-oriented and system-based.
It uses biological, cellular, and biochemical tools and emphasises regeneration and repair.	It uses mechanical, electrical, and computational tools and emphasises diagnostics and instrumentation.
It focuses on the development of biological substitutes to restore, maintain, or improve damaged tissues or organs using cells, biomaterials, and bioactive molecules.	It aims to improve diagnosis, treatment, monitoring, and rehabilitation through engineered solutions.
For example, it regenerates functional tissues such as skin, cartilage, bone, or cardiac tissue.	For example, it regenerates skin and repairs cartilage, bone, and cardiac tissue.

Artificial organs are more intertwined with biomedical engineering. Therefore, to further understand the scope of biomedical engineering, it is important to consider the manufacturing of artificial organs, which represents a critical development in contemporary medical science.

5. Manufacturing of Artificial Organs

An artificial organ is a man-made device, designed to replace or restore the function of a natural, failing, or missing body part. Organ manufacturing involves designing, preparation of

materials and tools, cell seeding, and tissue maturation. Therefore, organ manufacturing can be defined as 'producing bioartificial organs using living cells (adult cells, stem cells), along with other biomaterials (polymers, growth factors, bioactive agents or biochemical signals), and some advanced processing technologies.' The manufacturing process, in broad terms, consists of four major steps, which are (1) architectural predesign, (2) preparation of materials, (3) cell assembling (homogeneous/heterogeneous), and (4) post multi-tissue maturation. [1] Looking further into 3D bioprinting, biomaterials and printing techniques.

5.1 3D Bioprinting in Brief

3D printing plays a key role in manufacturing artificial organs. It is more efficient than other printing methods in several aspects, including flexible design, rapid prototyping, print-on-demand, and the production of strong, lightweight

parts. 3D printing refers to the layer-by-layer deposition of bioinks (tissue spheroids, microcarriers, and cell pellets). It has been used to construct 2D tissues for solid organs (e.g., complex organs: hollow tubes (blood vessels), bladder, and solid organs: kidneys).




Figure 3: Example of a step-by-step printing process

Source: AI Generated (Copilot)

Biomimicry, autonomous self-assembly, and mini-tissue are the building blocks of 3D bioprinting. (1) Biomimicry makes technological and industrial designs by copying natural processes. The main idea behind biomimicry is to observe nature, learn its processes, and try to solve the challenges already present in nature. (2) Self-assembly is a process where atoms, molecules or nanoscale building elements spontaneously organise themselves into ordered structures or patterns. This is achieved with the help of nanometre features without human intervention. It is low-cost and has high fabrication precision for nanofabrication. (3) Mini tissue is mainly the combination of both mimicry and self-assembly approaches. It comprises smaller functional building blocks of organs and tissues, such as nephrons in kidney tissue.

These strategies have been used in several bioprinting approaches to create 3D-printed constructs with desired functional, mechanical, or structural properties. 3D printing technology has biocompatible, biodegradable and antimicrobial properties. However, when used alone, it has low mechanical properties and slow gelation. Gelatin is used to make a hydrogel composite, thus leading to better osteogenic cell proliferation and differentiation (the process by which precursor cells transform into specialised bone-forming cells. This process increases the efficiency and reliability.) Though it has a few drawbacks, good printability at room temperature, high 3D construct shape, and good

biocompatibility can be achieved. The rapid cooling property also prevents cell damage caused by high-temperature processing during 3D printing. These different strategies and methods can produce a construct that can produce multiple components and properties simultaneously. For good printability, the materials used are very important. Therefore, material selection is one of the crucial steps in fabricating the 3D printed system. [2]

5.2 Biomaterials in Brief

Materials used for biomedical applications are mainly natural or synthetic polymers. Hence, they are broadly classified into Natural polymers and synthetic polymers. (1) Natural polymers are primarily similar to the human ECM (Extracellular Matrix) and have natural bioactivity, making the models closer to the original shape. Some of the naturally found polymers include gelatin, collagen, silk, and many other biocompatible polymers. (2) Synthetic polymers like PLA (Poly Lactic Acid), PGA (Poly Glycolic Acid), polyamides, and several other polymeric hydrogels can be functionalized and moulded with specific properties to match specifically designed applications. In comparison to natural polymers, synthetic polymers have a few disadvantages, such as poor biocompatibility, toxic degradation products, and loss of mechanical properties during degradation; however, they are widely used.




Figure 4: Example of natural polymers in a real application

Source: ResarchGate

Here, polymers originated from land and marine environments, and undergo 3D bioprinting to produce scaffolds such as

a) 3D printed ear-shaped scaffold

b) Cylindrical porous scaffold structure

c) Grid-patterned scaffold structure.

d) Flexible mesh-like scaffold held between tweezers.




Figure 5: Example of synthetic polymers in a real application

Source: ResearchGate

In this picture, a synthetic polymer combines with stem cells to form a biocompatible hydrogel along with some growth factors. The hydrogel is used in a 3D printer, and with the help of the hydrogel matrix, it forms 3D printed scaffolds. These scaffolds can help repair bones and damaged tissues.

Printability, Fabrication Compatibility, Chemical Stability, Cost Effectiveness, Biocompatibility, Degradation Kinetics and Byproducts, Structural and Mechanical Properties, and Material Biomimicry are some of the major factors in achieving the desired product (organ). [4] The design and capabilities of the printed construct are very much influenced by the types and properties of the bioprinting systems and printing techniques. [2]

5.3 Printing Techniques in Brief

Bioprinting technologies enable the accurate deposition of cells within a biomaterial, in specific orientations, to form complex structures using a computer-aided printer. Factors affecting 3D printing techniques include surface resolution, cell viability and the nature of biomaterials.

Inkjet bioprinting (Thermal inkjet printers, Acoustic inkjet printers), Extrusion bioprinting, and Laser-Assisted bioprinting are some of the most common printing methods.




Figure 6: Types of printing technologies, Source: ResearchGate

5.3.1 Inkjet Printing (A):

It involves using many tiny dots of ink so small that the naked eye could not see them. This involves the cell being deposited over a substrate using cell adhesion proteins, using a computer. It enables the establishment of precise spatial interrelationships between cells. Therefore, helping to create a 2D patterned tissue onto the flexible substrate.

5.3.2 Extrusion Printing (B):

A technique where the molten polymer is forced through a die to produce components of fixed cross-sectional areas. It is used to produce rods, sheets, films, wire insulation coating, etc. The material is pushed forward by a feeding screw and is forced through a die, thus forming into a continuous polymer product. This is an inexpensive, nonbiological 3D printing method.

5.3.3 Laser-Assisted Reproduction (C):

Laser-based bioprinting uses the laser-induced forward transfer phenomenon to deposit a very small amount of bioink in liquid or solid phase. It was initially developed to deposit metals onto receiver sheets, but it has been successfully applied in biological applications as well. DNA, cells, tissue, and organ printing are the typical applications where laser-assisted printing is used.

Some of the other printing techniques, which are less commonly used, are the Microvascular printing technique and Vat polymerisation. In the manufacturing of advanced artificial organs, Shape and resolution, Material heterogeneity (cells, growth factor and biomaterials), and other such factors can be easily achieved. Among all the different types of printing techniques, inkjet printing is used more commonly. This is due to its low cost, versatility and compact design.

In conclusion, the progressions in biomaterials have enormously affected artificial organs and organoid creation. Integrating biomimetic methods has enabled the development of biomaterials that closely mimic the structure and functions of natural tissues. This helps improve interactions between cells and supports tissue morphogenesis. The effective use of scaffold fabrication techniques and a better understanding of interactions between biomaterials and cells have accelerated progress toward the development of functional artificial organs and complex organoids.

Despite recent advancements, remaining problems still need to be addressed, including long-term biocompatibility, managing the immune response, and clinical translation. This approach will promote the development of functional, long-lasting, and biocompatible artificial organs and organoids, resulting in biomaterials. [2]

While advances in the manufacturing of artificial organs have significantly improved treatments, the increasing complexity of biomedical systems has created a need for more intelligent and adaptive technologies. In recent years, AI (Artificial Intelligence) has emerged as a powerful tool in biomedical engineering, enabling researchers to analyse complex biological data, optimise device design and improve the scope of biomedical engineering in many ways.

6. Effect of AI (Artificial Intelligence) in Healthcare

The replication of human intellect in robots built to carry out tasks that normally require cognitive abilities like learning, reasoning, and decision-making is known as AI. Machine learning, Natural Language Processing, and deep learning are some of the major subfields that fall under AI. The use of AI in the medical field offers several benefits, one of which is 'Telehealth', which refers to wearable devices. It has widened access to care for the elderly and differently abled people. Another example is that AI enables household and remote monitoring of health metrics, etc. AI, in recent years, has been used in all fields like medical imaging, healthcare, biotechnology, discovering and creating biomolecules, drugs and chemical structures, etc. Due to the vast usage of AI, a model developed by Google Health was evaluated in a real-world clinical setting, which outperformed human radiologists. Initially, this model was developed to detect breast cancer, but doctors and physicians must be aware of how to use AI in the best way in order to obtain the best results.




Figure 7: AI-assisted disease surveillance and response workflow

Source: ResearchGate

The figure illustrates an integrated, AI-driven healthcare framework for disease detection and control. The process begins with clinical sample collection and symptom detection by healthcare workers, followed by diagnostic assessment. Collected clinical and epidemiological data are then fed into AI-driven software, which analyses disease progression patterns, predicts spread, and evaluates potential control strategies. The analysed outputs are communicated to the global medical community, enabling evidence-based decision-making. These insights support coordinated actions, including pharmaceutical research and drug development, healthcare supply-chain optimisation, and implementation of quarantine and containment strategies, thereby strengthening rapid response and public health policy planning at a global scale. [5]

Late disease detection and the absence of early treatment and adequate healthcare facilities contribute significantly to complications and mortality. Accurate disease diagnosis often requires substantial time and testing, which can be prohibitively expensive, placing a financial strain on patients and their families. Additionally, prescribed medications may not always be tailored to the patient's specific needs or conditions. To address these challenges, AI offers a promising solution. Some of the key differences between traditional

and AI-based healthcare are that AI can adapt to a wide variety of problems and keeps learning. While traditional methods can only handle specific, predefined tasks. Other factors, such as organising, translating and huge datasets, come in handy with AI but not with the other method. The application of AI has proven to be highly promising in many aspects of healthcare. It also helps clinicians and patients, making the diagnosis, decision-making, treatment, and surgery of the disease simpler. Though access to care remains unequal, especially in poorer neighbourhoods far from cities, where hospitals and medical personnel tend to be concentrated. Such a difference could be overcome through the development of AI-based health systems that are simple, affordable, and readily available. Through early detection and forecasting, AI can prolong lives, decrease the rate of illness, and avoid death. One of the most impactful examples of AI improving medical devices is an AI-based radiology triage system. This system utilises AI algorithms to detect anomalies in medical images, such as CT scans, with high accuracy and speed. By identifying abnormalities early, the AI system enables assistance to radiologists in diagnosing conditions more quickly and accurately. This saves lives through early treatment and reduces risks. Although AI could transform biomedical engineering and medicine by optimising medical devices, technologies, and outcomes, and its efficiency has been undoubtedly remarkable, several ethical hurdles come forward when discussing the role of AI in healthcare. The legal framework defining the responsibilities of AI use and regulating its misuse is still at a developing stage. Data privacy and informed consent laws are another big loophole in AI development. While strict data confidentiality legislations may protect patient data, they hinder AI training and development in healthcare applications. On the other hand, tax regulations may infringe upon patient confidentiality and rights. Moreover, while AI can analyze vast amounts of data, it still struggles to fully grasp the complex medical knowledge necessary for accurate diagnosis and treatment, especially when it comes to understanding the context of a patient's condition. The integration of AI into healthcare brings up important ethical questions. One such pressing issue is figuring out who should be held responsible if an AI system makes a mistake, whether it is the developers, the healthcare providers, or someone

else. This highlights the importance of creating a system where AI supports human expertise rather than replacing it. By making AI more transparent and ensuring that it works alongside doctors, we can build trust and maximise its potential to improve healthcare and provide patients with the best care. [5]

Although the integration of artificial intelligence has improved the efficiency and adaptability of artificial organ technologies and biomedical engineering, a broader understanding requires an examination of the different types of artificial organs themselves. Biomedical engineering has enabled the development of several artificial organ systems by providing essential support and enhancing patient outcomes in various ways.

7. Stepping Into Artificial Organs

Biomedical engineering has significant importance; it has helped develop artificial organs such as the kidney, liver, heart, pancreas, and lungs. [3] Among these organs, the liver and the heart are the most common. Apart from this use, engineering and technology also come into play in other scenarios and rare cases, such as the skeletal, sensory, digestive, and reproductive systems. [8]

7.1 Artificial Heart

Examining the heart in greater detail, the field of heart transplantation has undergone a transformative evolution in medical research. It has become a medical milestone, offering a pivotal therapeutic option for individuals suffering from end-stage heart disease. In 1967, the first successful human-to-human heart transplant was performed, marking a significant leap in medical science. Only in the 1980s did this method become the preferred treatment for patients with end-stage heart failure. This method had significantly improved patient survival rates, which rose from a modest 30% between 1967 and 1973 to an encouraging 60% between 1974 and 1980. In the current era, this rate has soared to an impressive 90%. [7]




Figure 8: Long-term survival after heart transplantation across different eras, Source: JCVAOnline

This figure illustrates survival curves showing patient survival (%) as a function of years after heart transplantation across four eras: 1982–1991, 1992–2001, 2002–2008, and 2009–2016. A progressive improvement in survival is observed in successive eras, with median survival increasing from 8.6 years (1982–1991) to 12.4 years (2002–2008), while median survival for the most recent cohort remains unavailable due to limited follow-up. Survival differences between all eras are statistically significant ($p < 0.0001$).

The observed improvement in post-transplant survival reflects major advancements in biomedical engineering, including the development of artificial hearts and ventricular assist devices, improved biomaterials, enhanced device biocompatibility, and better integration of mechanical circulatory support as a bridge to transplant or destination therapy. These engineering innovations, combined with refined surgical techniques and post-operative monitoring systems, have significantly contributed to improved patient outcomes over time. Despite these advancements, the field faced a lot of challenges in the early stage, especially in the chronic shortage of donor organs, which severely limits the number of patients who can benefit from this life-saving procedure. Therefore, bringing the artificial heart into the picture, it is the most iconic example of biomedical engineering prowess. Designed to pump blood throughout the body, artificial hearts have evolved significantly since the first successful implantation. An advanced artificial heart uses 3D printing techniques to achieve detailed requirements. With the help of modern methods, scientists use advanced machines to mimic minute details and perform tasks such as enhancing implant viability and producing cardiac-specific extracellular matrices made from animal-derived bioink or decellularized cardiac tissue, as mentioned above. Using CT

(Computed Tomography) and MRI (Magnetic Resonance Imaging) data, they print hydrated materials such as alginate, collagen, and fibrin to build mechanically robust and complex 3D anatomical cardiac architectures. In fact, the world's first independently functioning artificial heart was completed on 3rd July 2001. The main pump of the heart was made of titanium and plastic and weighed about 1kg. It had an electronic control system to alter the blood flow according to the body's requirements. The only drawback was its size, which was too large for the female human body. Through advancements in genetic engineering and immunological strategies, artificial organ transplantation has overcome a lot of challenges but still has a few limitations. This short overview of heart transplantation, artificial hearts, the history and the revolution of transplantation sets the stage for future advancements in the field, offering renewed hope for improved patient care and outcomes. [10] While the development of an artificial heart was listed, similar technological approaches are applied to other vital organs, such as the liver.

7.2 Artificial Liver

Liver failure is a life-threatening condition due to different characteristics like liver dysfunction, cirrhosis, and decompensated hepatic disorders that often require transplantation for survival. Liver transplant has been associated with restoring normal body health, improving lifestyle, and extending a patient's lifespan by at least 15 years. There have been many challenges in the early phase of liver transplantation.




Figure 9: Survival rates of liver transplant recipients by age group,

Source: MDPI

This figure presents the survival rates (%) of liver transplant recipients at 1-, 3-, and 5-year follow-up intervals, stratified by age group (18–64 years and ≥ 65 years). Survival declines over time in both groups; however, younger recipients consistently have higher survival rates than older recipients. At 1 year, survival exceeds 90% in the 18–64 age group and approximately 88% in patients aged 65 years and above. By 5 years, survival decreases to around 78% and 67%, respectively, indicating an age-related difference in long-term

outcomes. The observed trends highlight ongoing challenges in liver transplantation, particularly in older patients, and underscore the importance of biomedical engineering innovations, including artificial liver support systems, bioartificial liver devices, advanced biomaterials, and extracorporeal detoxification technologies. These engineered systems play a critical role in supporting patients with end-stage liver disease as a bridge to transplantation or recovery,

improving peri-transplant stability and potentially enhancing post-transplant survival outcomes across age groups.

Liver grafting (allocating priority) plays a major role in liver transplantation. In the case of the United States, waiting list priority for the transplant was determined by the duration of waiting list time and clinical status before 1997. This method didn't help to reduce the mortality rate. Therefore, after further changes, the waiting list priority was categorised based on clinically assessed variables and laboratory-confirmed disease panels.

Some of the different liver transplant techniques include the Conventional Liver Transplantation technique, Piggyback technique, Partial Liver Transplantation procedures, Split-liver technique, LDLT (liver donor liver transplant), ECGs and Domino liver transplant.

In modern medical techniques, an artificial liver is a device designed using bio-artificial constructs containing liver cells (hepatocytes) to perform detoxification and metabolic functions. Recent developments include the use of 3D printing to create a stand that supports the growth and function of hepatocytes, enhancing the device's efficacy and longevity. Artificial livers hold potential not only for acute care settings but also for developing models to study liver diseases and drug metabolism. [6]




Figure 10: Example of an artificial liver device

Source: MDPI

The diagram shows the working principle of a Bioartificial Liver System. Blood from the patient is first processed through Plasmapheresis, where plasma is separated from blood cells. The plasma then passes through a pump, charcoal column, and oxygenator for detoxification and oxygen supply before entering a bioreactor containing Porcine Hepatocytes within a Hollow Fibre Membrane. These cells perform liver-like metabolic functions, after which the treated plasma is returned to the patient's bloodstream.

Ultimately, these technologies contribute to the development of bioartificial liver systems and other engineered organs, addressing the shortage of donor organs for transplantation.

Liver Transplantation has become a cornerstone in the field of organ transplantation, offering hope and extended life to countless individuals worldwide. As the trajectory of Liver Transplantation continues to ascend, it is essential to reflect on the progress made, acknowledge the challenges that lie ahead, and consider patient-centred care.

8. Conclusions

Biomedical engineering continues to move toward more integrated, precise, and patient-centred solutions in artificial organ development. Rather than focusing solely on current capabilities, future research must prioritize improving long-term biocompatibility, enhancing the scalability of 3D bioprinting technologies, and addressing the ethical and regulatory challenges associated with artificial intelligence-driven systems. In addition, advancing real-time monitoring, adaptive functionality, and seamless integration with the human body remains a critical area of exploration. Continued interdisciplinary collaboration will be essential to translate emerging technologies from research to clinical practice, ensuring they are reliable, cost-effective, and accessible across diverse healthcare settings. Emphasis must also be placed on expanding global access and improving the overall efficiency of these technologies. Ultimately, artificial organs hold the potential to redefine modern healthcare by reducing dependence on donor organs and enabling more personalised, sustainable, and widely accessible treatment solutions, thereby shaping the future of medicine.

Acknowledgements

I would like to express my sincere gratitude to my mentor, **Dr. Neelam, Biochemistry, Ph.D.**, for her invaluable guidance and support throughout the completion of this research paper. I am also deeply thankful to **Dr. R Raj Gowtham, M. S, M. Ch (Neurosurgery)** and **Dr. K. Natramizh, M. S, M. Ch (Plastic and Reconstructive Surgery)**, for their constructive feedback and insightful comments, which greatly contributed to the improvement of this work.

References

- [1] Xiaohong Wang, "Bioartificial Organ Manufacturing Technologies" Cell Transplant 2018 Nov 26; 28(1):5-17 [DOI] [PubMed]
- [2] Swikriti Tripathi, Subham Shekhar Mandal, Sudepa Bauri, Pralay Maiti, "3D bioprinting and its innovative approach for biomedical applications" MedComm (2020) 2022 Dec 24; 4(1):e194 [DOI] [PubMed]
- [3] Ishihara Leila, "The Development of Artificial Organs in Biomedical Engineering" Opinion Article. J Biomed Eng Med Dev, Vol.09 Iss.2 No:1000291 [LongDom]
- [4] K Praveena, Manjunatha, Ankita Awasthi, Amit Dutt, Irfan Khan, Preeti Maan and Raghad Ahmed Hussien "Biomaterials for Artificial Organs and Organoids- A Comprehensive Review" March 2024, E3S Web Conf., 505 (2024) 01004 [DOI] [ResearchGate]
- [5] Divya Tripathi, Kasturee Hajra, Aditya Mulukutla, Romi Shreshtha, "Artificial Intelligence in Biomedical

- Engineering and Its Influence on Healthcare Structure: Current and Future Prospects*” February 2025, 12(2):163 [DOI] [ResearchGate]
- [6] Eyad Gadour, “*Lesson learnt from 60 years of liver transplantation: Advancements, challenges, and future directions*” World J Transplant, 2025 Mar 18;15(1):93253 [DOI] [PubMed]
- [7] Yousaf Tanveer, Aleena Arif, Tamar Tsenteradze, Nabila N Anika, Danyal Bakht, Quratulain Fatima Masood, Maryam Affaf, Wajiha Batool, Indresh Yadav, Rayan W Gasim, Youssef Mohamed, Mohamed Abdelmonim Khogali Mohamed, Chukwuyem Ekhaton, Syed Naveed Mohsin, Rehman Khan, “*Revolutionising Heart Transplantation*” Cureus 2023 Sep 29;15(9):e46176 [DOI] [PubMed]
- [8] Deanna MacNeil, PhD, “*Artificial Organs: Innovating to Replace Donors and Dialysis*” Jan 20, 2023|Updated May 3, 2025 [TheScientist]
- [9] Joseph E. Murray, “*The Fight for Life*”. [HarvardMedicine]
- [10] Yuan Yuan, “*Analysis of the current status and development prospects of artificial hearts*” Jan 2024 Theoretical and Natural Science 29(1):108-111 [DOI] [ResearchGate]